Sector
Healthtech & bio
4$2bn$2bn0
Photo: Photo Credit: James Gathany
Content Providers: CDC/ Douglas / Wikimedia Commons, Public domainShionogi agrees to buy rare-disease drugmaker IntraBio for $2 billion
Shionogi is paying $2 billion in cash for a privately held biotech whose only product, Aqneursa, brought in about $68 million last year and won a second FDA approval less than three weeks before the deal.
$2bn$55mStage n/aCorporate
Latest in Healthtech & bioCharlotte · Healthtech & bioPritzker-backed Emergence acquires Charlotte patient-outcomes software maker Clinect Healthcare
San Diego · Healthtech & bioFresh Clinics acquires Spakinect, adding a telehealth exam network for US med spas
Noida · Healthtech & bioHoola Health acquires UpTodd to build a paid programme for a child's first 1,000 days
San Diego · Healthtech & bioFresh Clinics acquires Spakinect, adding a telehealth exam network for US med spasNoida · Healthtech & bioHoola Health acquires UpTodd to build a paid programme for a child's first 1,000 days